Medication non-adherence in inflammatory bowel diseases is associated with disability

Jonathan Perry; Andy Chen; Viraj Kariyawasam; Glen Collins; Chee Choong; Wei Ling Teh; Nikola Mitrev; Friedbert Kohler; Rupert Wing Loong Leong

doi:10.5217/ir.2018.00033

Articles

Page Path: HOME > Intest Res > Volume 16(4); 2018 > Article

Original Article Medication non-adherence in inflammatory bowel diseases is associated with disability: Jonathan Perry¹, Andy Chen², Viraj Kariyawasam³, Glen Collins³, Chee Choong³, Wei Ling Teh³, Nikola Mitrev¹, Friedbert Kohler², Rupert Wing Loong Leong^1,2,3,; Intestinal Research 2018;16(4):571-578.
DOI: https://doi.org/10.5217/ir.2018.00033
Published online: October 10, 2018

¹Sydney Medical School, University of Sydney, Sydney, Australia

²Faculty of Medicine, University of New South Wales, Sydney, Australia

³Gastroenterology and Liver Services, Concord Hospital, Sydney, Australia

Correspondence to Rupert Wing Loong Leong, Gastroenterology and Liver Services, Concord Hospital, Hospital Rd, Sydney 2139, Australia. Tel: +61-2-9767-6111, Fax: +61-2-9767-6767, E-mail: rupertleong@outlook.com

• Received: March 7, 2018 • Revised: June 11, 2018 • Accepted: June 18, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

8,952 Views
173 Download
35 Web of Science
38 Crossref
40 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Acknowledgments
REFERENCES

Abstract

Background/Aims
Medication non-adherence is common in inflammatory bowel diseases (IBD). The short-term consequences of non-adherence include increased disease relapse but the long-term impact upon patients in terms of daily functional impairment are less well characterized. Identifying negative outcomes, such as disability, may encourage adherence.
Methods
Consecutive ambulatory IBD subjects completed the Medication Adherence Rating Scale (MARS; non-adherence defined as ≤16), Inflammatory Bowel Diseases Disability Index (IBD-DI; disability: <3.5) and Beliefs about Medicines Questionnaire (high necessity/concerns: ≥16). The primary outcome was the association between medication non-adherence and disability. Secondary outcomes were the predictors of these outcomes.
Results
A total of 173 subjects on IBD maintenance medications were recruited (98 Crohn’s disease, 75 ulcerative colitis: median IBD-DI, –5.0; interquartile range [IQR], –14.0 to 4.0 and median MARS, 19.0; IQR, 18 to 20) of whom 24% were non-adherent. Disability correlated significantly with medication non-adherence (r=0.38, P<0.0001). Median IBD-DI for non-adherers was significantly lower than adherers (–16.0 vs. –2.0, P<0.0001). Predictors of disability included female sex (P=0.002), previous hospitalization (P=0.023), management in a referral hospital clinic (P=0.008) and medication concerns (P<0.0001). Non-adherence was independently associated with difficulty managing bowel movements (odds ratio [OR], 3.71; 95% confidence interval [CI], 1.50–9.16, P=0.005), rectal bleeding (OR, 2.69; 95% CI, 1.14–6.36; P=0.024) and arthralgia/arthritis (OR, 2.56; 95% CI, 1.11–5.92; P=0.028).
Conclusions
Medication non-adherence was associated with significantly increased disability in IBD. Female gender, higher disease severity and medication concerns were additional predictors of disability.
Keywords: Crohn disease; Colitis, ulcerative; Inflammatory bowel diseases; Compliance; Drug

INTRODUCTION

Inflammatory bowel diseases (IBD) are chronic immune-mediated inflammatory conditions encompassing UC and CD [1]. The prevalence of these relapsing and remitting disorders has increased over time and they continue to be associated with significant morbidity [1,2]. Persistently active disease is associated with debilitating gastrointestinal symptoms, extraintestinal manifestations, the development of complications and bowel resection [3,4]. IBD has been associated with a reduced quality of life [5]. Quality of life, however, is a subjective measure of coping strategies [6]. Disability is increasingly recognized as a more objective means of quantifying an illnesses’ impact on day-to-day living, and is defined by the World Health Organization (WHO) as “any restriction or lack of ability to perform an activity in the manner or within the range considered normal.” [7] The Inflammatory Bowel Diseases Disability Index (IBD-DI) is a tool that measures the extent of functional impairment and disease burden in the IBD population [8]. The IBD-DI is based upon the WHO’s ICF (International Classification of Functioning, Disability and Health) core set which provides a framework for evaluating disability in terms of the interaction between the patients underlying illness and contextual environmental factors [8,9]. The IBD-DI has been validated and correlated with disease activity and quality of life in both CD and UC [10]. It also demonstrated real-life validity against decreased work productivity in IBD subjects from a referral clinic and increased direct and indirect healthcare cost in a population-based postoperative IBD cohort [10,11].

Medication non-adherence occurs in up to 45% of IBD patients and is associated with increased symptoms and relapse rates [12]. Non-adherence can be further categorized as intentional (deliberately stopping prescribed medications or altering their prescribed regime) and non-intentional (such as accidentally forgetting to take medications). The type of non-adherence may have implications for clinical outcomes and may have unique drivers. Unfortunately there has been no consistent predictor of non-adherence although some studies have identified younger age, full-time employment, shorter duration of disease, treatment type, psychological factors such as a strong emotional response and loss of response to therapy as possible risk factors [12-15]. Non-adherence in IBD has been shown to be difficult for physicians to identify [16]. To date there has been no simple and durable intervention that improves adherence rates [12].

The impact of non-adherence includes increased risk of IBD relapse, increased disease activity and increased healthcare costs [17,18]. The impact of non-adherence upon the day-to-day functioning of patients is less well characterized. Cumulative flares might result in cumulative intestinal complications, need for treatment escalation towards more potent medications and surgery. In the absence of a proven strategy that improves medication adherence, identifying the negative consequences of non-adherence might help convince patients to adhere to medications in order to avoid disability. Behavioral change might be expected from understanding the disabling consequences of recurrent flares. The primary aim of the study, therefore, was to identify the relationship between non-adherence and functional outcomes in IBD. Demographic, clinical and attitudinal factors were also assessed to determine predictors of adherence or disability.

METHODS

This was a cross-sectional non-interventional study to explore the association between medication non-adherence and disability. Disability is a concept that patients can relate to, being the result of many chronic diseases. The secondary outcome measures were the predictors of disability and medication non-adherence as well as the impact of medication acceptance on adherence.

1. Subjects

Consecutive ambulatory patients aged ≥16 years with a definitive diagnosis of CD or UC and ≥6 months of follow-up were prospectively recruited. Patients recruited were within the catchment population of the Sydney IBD Cohort, which has a well-characterized population [19]. Australia has a free universal healthcare system allowing subjects to be recruited from the full spectrum of socioeconomics. Inclusion criteria were being prescribed IBD maintenance medications. Exclusion criteria included insufficient English literacy and active psychological diagnoses such as mood disorders that impair day-to-day functioning.

Clinical and demographic information was obtained through self-report confirmed by their medical records. The data obtained included: demographics, IBD phenotype, duration of disease, recruitment from a dedicated IBD referral clinic or from private practice, membership of the patient support organization Crohn’s and Colitis Australia (CCA), previous hospitalization or surgery related to IBD and the respondents’ current medication regimen.

2. Procedures

Participant completed 3 questionnaires: IBD-DI, Medication Adherence Rating Scale (MARS), and the Beliefs about Medicines Questionnaire (BMQ) administered by an independent trained researcher separate to the medical consultation to reduce response bias.

3. IBD Disability Index

The IBD-DI is a validated questionnaire that measures disability in CD and UC. It has been validated for construct, discriminant ability, sensitivity to change and responsiveness [10]. The IBD-DI comprises of 28 questions examining functional capabilities of patients with respect to the ICF core set and is significantly associated with disease activity and treatment received [8,9]. The tool is divided into 5 domains of overall health, body function, body structures, activity participation and environmental factors. The extent of patients limitations and disability are examined with respect to areas such as sleeping, mood, abdominal pain, bowel frequency, regulating defecation, participation in social events and work or school and exacerbating effects of medication, food, family and healthcare professionals. As a part of this study, the original questionnaire was reworded from a Flesch-Kincaid grade level 9 to grade level 6, an improvement recommended by previous studies, where subjects found the questionnaire would be improved with language simplification. A composite score [10] represents the patients’ extent of functional impairment or disability that ranges from 22 to –80. A more negative score correlates with greater disability. The IBD-DI demonstrates construct validity against the Inflammatory Bowel Disease Questionnaire (IBDQ), the disease activity indices CDAI for CD and the Mayo score in UC, predicts workforce participation and responsiveness [10].

4. Medication Adherence Rating Scale

The MARS is a validated tool that has previously been utilized to evaluate adherence in IBD [20,21]. Four statements relating to adherence are each scored on a 5-point Likert scale. The use of a scale avoids dichotomous “yes” or “no” answers that might result in response bias. Response bias is expected for any study of adherence where subjects exaggerate with medically-responsible answers. The MARS score ranges from 4 to 20 where a score of ≤16 was defined as medication non-adherence. MARS is self-administered, easy to understand and completed confidentially in isolation remote to the consultation. The prescribing physician is blinded to the score to encourage patient honesty. MARS has been tested in IBD and correlates with markers of medication adherence such as serum drug levels and script dispensing data [21,22].

5. Beliefs about Medicines Questionnaire

The BMQ is a validated survey tool that examines patient attitudes towards taking medications [14,21,23]. It is based upon the beliefs about medications framework and consists of 10 items divided into statements exploring perceptions of the necessity for maintenance medications and the level of concern around their potential adverse effects. Respondents indicate their concordance with these statements on a 5-point Likert scale. A score is calculated for each of the domains of “medication concern” and “medication necessity.” Scores range from 5 to 25 where respectively a higher score indicates a greater extent of concern regarding taking medications or a higher level of perceived necessity to take therapy. A score of ≥16 in these 2 domains was defined as either “high concerns” or “high necessity” respectively. “Medication acceptance” was defined as perception of medications as being “high necessity” and “low concerns,” which is considered to be the ideal attitude towards adherence to maintenance medications.

6. Sample Size Calculation

Sample size calculation was based on a quarter of IBD subjects meeting the threshold of disability from a previous study [10] and a clinically meaningful doubling of disability resulting from medication non-adherence. Another study had identified the prevalence of medication-adherers to be 3-fold higher than medication non-adherers in IBD [21]. Based on a 2-sample proportional analysis for the trial to have 80% power on a 2-sided alpha level of 0.05, 168 consecutive subjects would be need to be recruited with a ratio of 3 medication adherers for every 1 medication non-adherer to detect a doubling of disability.

7. Statistical Analysis

Statistical analysis was used to evaluate associations between the MARS, BMQ and IBD-DI questionnaires and to determine the predictive clinical or demographic factors. Continuous variables were analyzed as non-parametric data using Spearman correlation, Mann-Whitney U-test for unpaired- and Kruskal-Wallis test for 3-continuous variables. Categorical variables were compared with chi-square or Fisher exact tests. Multivariate binomial logistic regression was utilized to determine the specific disability index outcomes that were independently associated with nonadherence. Multivariate linear regression modeling was used in analyzing adherence, beliefs about medicines and disability questionnaire scores. Analysis was performed using IBM SPSS version 22.0 (IBM Corp, Armonk, IL, USA). A P-value <0.05 was deemed statistically significant.

8. Ethical Consideration

Informed consent was obtained for all subjects involved in this study. The study was approved by the Concord Hospital and South Western Sydney Local Health District Human Research and Ethics Committees (Reference numbers: LNR/14/CRGH/69; LNRSSA/15/LPOOL/313) in accordance with to the ethical guidelines of the 1975 Declaration of Helsinki (6th revision, 2008).

RESULTS

1. Study Population

In total 173 respondents (98 CD, 75 UC; median age 40.0, 51% females) were prospectively recruited for this study between March 2014 and September 2015. Through consecutive recruitment, specialist referral IBD clinic patients made up 64% of the cohort while the remainder were recruited from private gastroenterology practices. The duration of illness was not significantly different between care setting (P =0.82). However, referral clinic patients were more likely to have CD than those seen in private practice (71% vs. 55%, P=0.02). Maintenance therapy with an immunomodulator was more common in CD versus UC (72% vs. 32% P<0.01). Anti-tumor necrosis factor therapy utilization was more prevalent amongst CD patients than those with UC (37% vs. 1% P<0.01). Mesalazine use in CD was 36% compared to 89% amongst the UC cohort (P<0.01). Previous IBD-related hospitalization and surgery respectively was reported in 47% and 32% of CD patients compared to 28% and 5% of UC patients (P<0.01). Our population data set was not-normally distributed and was therefore analyzed using non-parametric tests.

2. Non-Adherence and Disability

Of all subjects recruited, 24% (n=42) were non-adherent with their IBD maintenance medications. Non-adherers had similar baseline characteristics to adherers (Table 1). Medication non-adherence correlated significantly with worse disability (correlation of MARS adherence score vs. IBD-DI, r=0.38, P<0.0001; non-adherers median IBD-DI score –16.0 [IQR, –26.0 to –6.0] vs. adherers –2.0 [IQR, –9.0 to 5.0], P<0.0001) (Fig. 1). Non-adherence correlated significantly with perceived non-necessity of medications (r=0.22, P=0.004) and with concern about medical treatment (r=0.32, P<0.0001). Non-adherent patients demonstrated significant associations with disability in the composite IBD-DI and in all of its 5 domains of overall health, body function, body structures, activity participation and environmental factors (Table 2).

3. Factors Affecting Disability

Disability was not associated with IBD disease phenotype (P=0.41) or IBD duration greater than 5 years (P=0.39). However, disability was significantly association with previous hospitalization (P=0.010), previous surgery (P=0.035), the use of corticosteroid therapy (P =0.007), management through a referral clinic (P <0.0001) and female sex (P =0.002) (Table 3). Independent predictors of poorer functional outcomes on IBD-DI linear regression were high medication concern (P <0.0001), management through a referral clinic (P =0.008), previous hospitalization (P =0.023), and female sex (P =0.008).

4. Clinical Features Associated with Non-Adherence

On multivariate binary logistic regression 3 disease features were identified as being independently associated with medication non-adherence. These are: difficulty managing bowel movements (OR, 3.71; 95% CI, 1.50–9.16; P =0.005), the presence of rectal bleeding (OR, 2.69; 95% CI, 1.14–6.36; P =0.024) and the presence of arthralgia or arthritis (OR, 2.56; 95% CI, 1.11–5.92; P =0.028) (Table 4). Anxiety trended towards significance within the model (OR, 2.83; 95% CI, 0.91–8.81; P =0.073) while other functional outcomes examined in the IBD-DI demonstrated no significant independent association with adherence.

DISCUSSION

Medication non-adherence in IBD is associated with increased risk of relapse and healthcare utilization [12,17,24,25]. These intangible concepts, however, might be insufficient to motivate patients in improving their adherence. Disability is a sustained, recognizable, relevant and self-identifiable concept that might be a greater motivational force to improve adherence. This study demonstrated a significant association between medication non-adherence and disability. Medication non-adherence was significantly associated with impaired activity pariticipation and impairment of all IBDDI domains. Disability was also significantly associated with symptoms of flares, requirement for corticosteroids, IBDrelated hospitalization and surgery. The avoidance of disability, therefore, becomes a shared goal between the physician and patient. As such, the translatable benefits of this study might be in shaping a conversation that motivates patients to improve their adherence in order to prevent or reverse disability. The quantification of disability through the IBD-DI may also have utility at the level of healthcare organisations as significant outcome measure or quality indicator [26].

Three specific symptoms of IBD are significantly independently associated with medication non-adherence. Arthralgia and rectal bleeding are the symptoms associated with non-adherence with greatest frequency, while difficulty managing defecation has the strongest association within the model. All of these factors are prevalent in active IBD and have been associated with impaired quality of life and impaired social engagement [27-30]. Presentation with these symptoms, therefore, might alert the physician of possible medication non-adherence.

Apart from non-adherence, disability was also independently associated with previous hospitalization, management in an IBD referral center, having high concerns over medications and female sex. Previous hospitalization and management in a referral center represent greater disease severity. Disability in IBD has also been found to be associated with female sex [10,31]. Symptoms of anxiety and depression that might result in avoidance of using medications are also associated with disability [32]. Managing medication non-adherence, therefore, might require a targeted approach in identifying high-risk subjects, those with severe disease and treatment of psychological comorbidities. Promising preliminary results have been seen with a pharmacist-led personalized educational intervention [33].

This study has several limitations. Firstly, although there was a strong association between non-adherence and disability, causality cannot be confirmed. Although the logic is that non-adherence results in cumulative disease flares that result in chronic disease activity and/or irreversible intestinal damage, the alternative explanation that cumulative disability leads to medication non-adherence is possible. This was an observational cross-sectional study which inherently is limited in its power to detect causality and is able to only establish associations. Ultimately a randomized controlled longitudinal study is required to demonstrate decreased disability through improved adherence. Although there is a clear linear correlation between disability and adherence score the strength of this correlation is reduced somewhat due to a wide range of IBD-DI scores for a given range of the MARS. Secondly, adherence level may fluctuate over time. However, we recently demonstrated that baseline adherence or any improvement in adherence through counseling is consistent even when followed up for 2 years [33]. Medication adherence is, therefore, likely a feature of the subjects’ pervasive beliefs and perception. Thirdly, this was not a population-based study. However, the subjects were recruited from both referral and private practice settings to provide a range of IBD disease characteristics. Our data are consistent with a French population-based study [31] that also demonstrated greater disability levels in females and those with arthralgia/arthritis, and the lack of association between disability with IBD phenotype and duration of IBD. It is likely, therefore, that this study can be generalizable. Fourthly adherence and disability data relied on patient self-reporting. However, the MARS is a commonly-used tool that reflects real-world multiple medication usage rather than limiting to either single drug class or drugs that have bioassays. Unlike the Morisky et al. [34] MMAS-8 tool MARS uses Likert scales in eliciting subject responses. By avoiding dichotomous “yes” or “no” replies, subjects are less likely to exaggerate their answers towards those that are more “medically responsible.” Similarly the IBD-DI has been validated against work productivity and quality of life specific to IBD [10]. Beliefs about Medications Questionnaire has been also previously evaluated in IBD to provide certain degrees of external validation [14,20]. In addition we have not examined the impact of adherence to non-pharmacological treatments which may also impact significantly on disability. If a larger sample size had allowed for stratification by phenotype this may have been informative, however overall there was no association between phenotype and adherence/disability. By design patients in this study did not complete survey tools to assess diseases activity such as the CDAI or pMayo scores.

The IBD-DI has previously been validated [10] against these disease activity measures and its use as an independent outcome measure as in this study enhances its utility, additionally it was predicted that patients would experience a degree of survey fatigue if the set of administered tools was expanded any further. Laboratory or endoscopic data was not used to evaluate the results in this study as our aim was to assess functional impairment/disability broadly rather than disease activity or detect episodes of relapse. Strengths of the study include a recruitment sample size that was achieved, the use of validated tools for IBD and not limiting the subjects to tertiary hospital subjects.

In conclusion, poor medication adherence to IBD maintenance therapy is strongly associated with an increased level of disability. Uncontrolled active IBD through medication non-adherence might result in flares, need for hospitalization and eventual treatment escalation. Predictors of both non-adherence and disability included the presence of anxiety symptoms while female sex and higher disease severities as evident by prior hospitalization predicted increased disability. Patients with these adverse features require specific management in order to reduce their risk of long-term disability. The implementation of programs targeted towards addressing medication concerns and knowledge deficits in at risk patients may lead to the reversal of non-adherence in order to reduce long-term functional impairment.

NOTES

FINANCIAL SUPPORT

The authors received no financial support for the research, authorship, and/or publication of this article.

CONFLICT OF INTEREST

All authors declare that they have no conflicts of interest with respect to this work. Dr. Rupert Wing Loong Leong reports advisory board membership from Takeda, Janssen, AbbVie, MSD, Pfizer, Ferring and Aspen unrelated to this research.

AUTHOR CONTRIBUTION

Conceptualization: JP, AC, RL. Methodology: JP, AC, RL, CC, GC, WLT. Formal analysis: JP, AC, RL, FK, NM, WLT, VK. Project administration: RL, GC, WLT, CC Visualization: JP, AC. Writing - original draft: JP, AC RL, FK, GC. Writing - review and editing: JP, RL, FK, VK, CC, WT, NM, GC. Approval of final manuscript: all authors.

Acknowledgments

The authors acknowledge Wei Xuan, Ingham Institute of Applied Medical Research, UNSW, Sydney, New South Wales, Australia, for statistical support.

Fig. 1.

Correlation between Medication Adherence Rating Scale (MARS) and the Inflammatory Bowel Diseases Disability Index (IBD-DI) according to acceptance of medications. Medication acceptance is defined as a subject’s perception of high medication necessity and low concerns according to their Beliefs about Medicines Questionnaire.

Table 1.

Demographics of Respondents and Outcome Measures According to Medication Adherence

	Adherent subjects (n=131)	Non-adherent subjects (n=42)^a	P-value
Demographic
Age (yr)	39 (26.5 to 51.5)	42 (30.75 to 53.25)	0.690
Female sex	65 (49.6)	24 (57.1)	0.400
CD	79 (60.3)	19 (45.2)	0.090
Referral hospital clinic attendance	86 (65.6)	5 (59.5)	0.470
Married/relationship	70 (53.4)	24 (57.1)	0.680
Crohn's and Colitis Australia membership	16 (12.2)	8 (19.0)	0.260
Previous IBD related hospitalization	52 (39.7)	15 (35.7)	0.640
Previous IBD related surgery	26 (19.8)	9 (21.4)	0.820
Medication regimen
Mesalazine	73 (55.7)	29 (69.0)	0.130
Immunomodulator	76 (58.5)	19 (45.2)	0.150
Corticosteroid	31 (23.7)	9 (21.4)	0.760
Anti-tumor necrosis factor α agent	32 (24.4)	5 (11.9)	0.085
Key questionnaire outcome measures
High medication concerns	58 (44.3)	31 (73.8)	0.001
High medication necessity	121 (92.4)	33 (78.6)	0.013
Medication acceptance	66 (50.4)	8 (19.0)	<0.001
Disability (IBD-DI score <3.5)	94 (71.8)	38 (90.5)	0.013
IBD-DI (score)	–2 (–9 to 5)	–16 (–26 to –6)	<0.001

Value are presented as median (interqutile range) or number (%).

^a Non-adherence defined by Medication Adherence Reporting Scale score ≤16, range 4–20.

IBD-DI, Inflammatory Bowel Diseases Disability Index.

Table 2.

IBD-DI Scores According to the International Classification of Functioning Domains Comparing Adherent versus Non-Adherent Subjects

Domain	IBD-DI score		P-value
Domain	Adherent subject (n=131)	Non-adherent subjects (n=42)	P-value
Overall health	–1 (–1.5 to 1.5)	–2 (–3 to –3)	<0.001
Body function	–6 (–10 to –2)	–11 (–16.6 to –5.4)	<0.001
Body structure	2 (1 to 3)	0 (–1.3 to 1.3)	<0.001
Activity participation	–2 (–4.5 to 0.5)	–6 (–9.5 to –2.5)	<0.001
Environmental factors	6 (2.5 to 9.5)	3 (0 to 6)	<0.001
Total score	–2 (–9.0 to 5.0)	–16 (–26.0 to –6.0)	<0.001

Values are presented as median (interquartile range).

IBD-DI, Inflammatory Bowel Diseases Disability Index.

Table 3.

Factors Associated with Disability as Measured by IBD-DI

	Median difference in IBD-DI score	P-value
Socio-demographic
Age	–0.032^a	0.670
Female sex	–7.0	0.002
Married/relationship	–1.0	0.700
Crohn's & Colitis Australia membership	–1.5	0.730
Tertiary IBD clinic management	–5.5	<0.001
Disease characteristics
Diagnosis greater than 5 years ago	–3.0	0.390
UC diagnosis	1.0	0.405
Previous IBD related hospitalization	–4.5	0.010
Previous surgery	–4.0	0.035
Treatment modalities
5-ASA	0.5	0.500
Immunomodulator	–1.0	0.450
Steroids	–5.5	0.007
Biologicals	2.0	0.770
Beliefs about medications
High concerns	–5.0	<0.001
Low necessity	4.0	0.800
Lack of acceptance	–7.5	<0.001
Medication related behavior
Non-adherence	–14.0	<0.001

^a Rho.

IBD-DI, Inflammatory Bowel Diseases Disability Index; 5-ASA, 5-aminosalicylic acid.

Table 4.

Logistic Regression Model of Disease Features Associated with Medication Non-Adherence

Clinical outcome	OR (95% CI)	β Coefficient	P-value
Fatigue	2.60 (0.71–9.46)	0.96	0.150
Low mood	0.53 (0.18–1.55)	–0.63	0.250
Anxiety	2.83 (0.91–8.81)	1.04	0.073
Abdominal pain	0.46 (0.17–1.23)	–0.78	0.120
Difficulty managing defecation	3.71 (1.50–9.16)	1.31	0.005
Presence of liquid stools	0.58 (0.23–1.47)	–0.54	0.250
Weight loss	1.74 (0.67–4.51)	0.55	0.260
Rectal bleeding	2.69 (1.14–6.36)	0.99	0.024
Arthralgia/arthritis	2.56 (1.11–5.92)	0.94	0.028

REFERENCES

1. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015;12:205–217.Article PubMed PDF
2. Ko Y, Butcher R, Leong RW. Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World J Gastroenterol 2014;20:1238–1247.Article PubMed PMC
3. Vatn MH. Natural history and complications of IBD. Curr Gastroenterol Rep 2009;11:481–487.Article PubMed
4. Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013;10:585–595.Article PubMed PDF
5. Lix LM, Graff LA, Walker JR, et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1575–1584.Article PubMed
6. Peyrin-Biroulet L. What is the patient’s perspective: how important are patient-reported outcomes, quality of life and disability? Dig Dis 2010;28:463–471.Article PubMed
7. World Health Organization. Document A29/INFDOCI/1. Geneva: WHO, 1976.
8. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61:241–247.Article PubMed
9. Lo B, Prosberg MV, Gluud LL, et al. Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. Aliment Pharmacol Ther 2018;47:6–15.Article PubMed
10. Leong RW, Huang T, Ko Y, et al. Prospective validation study of the International Classification of Functioning, Disability and Health score in Crohn’s disease and ulcerative colitis. J Crohns Colitis 2014;8:1237–1245.Article PubMed PDF
11. Lee Y, McCombie A, Gearry R, et al. Disability in restorative proctocolectomy recipients measured using the Inflammatory Bowel Disease Disability Index. J Crohns Colitis 2016;10:1378–1384.Article PubMed PDF
12. Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf 2011;10:863–870.Article PubMed
13. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010;105:525–539.Article PubMed PDF
14. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007;102:1417–1426.Article PubMed
15. van der Have M, Oldenburg B, Kaptein AA, et al. Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study. J Crohns Colitis 2016;10:549–555.Article PubMed PMC PDF
16. Trindade AJ, Ehrlich A, Kornbluth A, Ullman TA. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011;17:599–604.Article PubMed
17. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009;29:247–257.Article PubMed
18. Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res 2017;15:434–445.Article PubMed PMC
19. Selinger CP, Andrews JM, Titman A, et al. Long-term follow-up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:644–650.Article PubMed
20. Horne R, Parham R, Driscoll R, Robinson A. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:837–844.Article PubMed
21. Selinger CP, Eaden J, Jones DB, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2199–2206.Article PubMed
22. Fialko L, Garety PA, Kuipers E, et al. A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res 2008;100:53–59.Article PubMed
23. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psych Health 1999;14:1–24.Article
24. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008;53:1020–1024.Article PubMed
25. Sellin J. Disability in IBD: the devil is in the details. Inflamm Bowel Dis 2010;16:23–26.Article PubMed
26. Berry SK, Melmed GY. Quality indicators in inflammatory bowel disease. Intest Res 2018;16:43–47.Article PubMed PMC
27. Brakenhoff LK, van der Heijde DM, Hommes DW. IBD and arthropathies: a practical approach to its diagnosis and management. Gut 2011;60:1426–1435.Article PubMed
28. Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1–23.Article PubMed PDF
29. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 2006;55 Suppl 1:i1–i15.Article PubMed
30. Norton C, Dibley LB, Bassett P. Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life. J Crohns Colitis 2013;7:e302–e311.doi: 10.1016/j.crohns.2012.11.004.Article PubMed PDF
31. Gower-Rousseau C, Sarter H, Savoye G, et al. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut 2017;66:588–596.Article PubMed
32. Chan W, Shim HH, Lim MS, et al. Symptoms of anxiety and depression are independently associated with inflammatory bowel disease-related disability. Dig Liver Dis 2017;49:1314–1319.Article PubMed
33. Tiao DK, Chan W, Jeganathan J, et al. Inflammatory bowel disease pharmacist adherence counseling improves medication adherence in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2017;23:1257–1261.Article PubMed
34. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008;10:348–354.Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju
Intestinal Research.2025; 23(1): 37. CrossRef
Understanding Medication Nonadherence in Crohn’s Disease Patients: A Qualitative Evaluation
Robert E Brady, Jessica K Salwen-Deremer, Natalie C Tunnell, Michael W Winter
Inflammatory Bowel Diseases.2024; 30(11): 2046. CrossRef
Attitudes to medication and effects of IBD nursing service among patients with inflammatory bowel disease in Taiwan
Chen‐Ta Yang, Tsui‐Chun Hsu, Yang‐Yuan Chen, Siou‐Ping Huang, Hsu‐Heng Yen
Advances in Digestive Medicine.2024; 11(3): 162. CrossRef
COMPLIANCE AND QUALITY OF LIFE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
R.J. JAMOLOVA, D.K. MUKHABBATOV, D.T. RAKHMONOV, S.G. ALI-ZADE
AVICENNA BULLETIN.2024; 26(1): 76. CrossRef
High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease
Esma H. San, Angelique Egberts, Caroline W. Th. van Dijck - van Boetzelaer, Rachel L. West, Erwin C. Vasbinder
European Journal of Clinical Pharmacology.2024; 80(7): 1089. CrossRef
MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
Ferdinando D'Amico, Francesca Lusetti, Laurent Peyrin-Biroulet, Silvio Danese
Digestive and Liver Disease.2024; 56(9): 1425. CrossRef
Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions
Caterina Mercuri, Maria Catone, Vincenzo Bosco, Assunta Guillari, Teresa Rea, Patrizia Doldo, Silvio Simeone
Healthcare.2024; 12(12): 1210. CrossRef
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study
Patrick Gagnon-Sanschagrin, Myrlene Sanon, Mikhaïl Davidson, Cynthia Willey, Sumesh Kachroo, Timothy Hoops, Dominik Naessens, Annie Guerin, Martin Cloutier
Journal of Medical Economics.2024; 27(1): 931. CrossRef
A Practical Approach to Identify Non-Adherence to Mesalamine Therapy in Inflammatory Bowel Disease
Filippo Vernia, Giorgia Burrelli Scotti, Raffaele Borghini, Mario Muselli, Stefano Necozione, Giovanni Moretta, Lorenza Scurti, Giuseppe Donato
Gastroenterology Insights.2024; 15(3): 754. CrossRef
Use of Complementary and Alternative Therapies in People with Inflammatory Bowel Disease
Laura Frank, Kelly Lambert
International Journal of Environmental Research and Public Health.2024; 21(9): 1140. CrossRef
Obstacles to Medication Adherence for Patients with Inflammatory Bowel Disease: A Qualitative Study in East China
Fen Xu, Jingjing Xing, Mingna Fan, Zhiping Zhu, Yan Chen, Wen Hu, Yunxian Zhou
Patient Preference and Adherence.2024; Volume 18: 2481. CrossRef
A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan
Yanfang Liu, Choo Hua Goh, Hong Qiu, Kuan-Chih Huang, Hsingwen Chung, Carine Saadoun
Annals of Pharmacotherapy.2023; 57(9): 1053. CrossRef
Development and implementation of a laboratory monitoring dashboard to reduce treatment gaps in inflammatory bowel disease
Miranda Kozlicki, Bridget Lynch, Tony Donoho, Patrick Nichols, Autumn D Zuckerman
American Journal of Health-System Pharmacy.2023; 80(Supplement): S55. CrossRef
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
Edward V. Loftus, Jenny Griffith, Ezequiel Neimark, Alexandra Song, Kori Wallace, Sujani Nannapaneni, Ji Zhou, Rachel Byrne, Kristina Kligys, Yinuo Pang, Xiaomei Liao, Jasmina Kalabic, Marla Dubinsky
Advances in Therapy.2023; 40(5): 2311. CrossRef
Development and Validation of a Remote Monitoring Tool for Assessment of Mild, Moderate, and Severe Infections in Inflammatory Bowel Disease
Ashkan Rezazadeh Ardabili, Dirk van Esser, Dion Wintjens, Mia Cilissen, Debbie Deben, Zlatan Mujagic, Fritzi Russ, Laurents Stassen, Adriaan A Van Bodegraven, Dennis Wong, Bjorn Winkens, Daisy Jonkers, Mariëlle Romberg-Camps, Marie J Pierik
Journal of Crohn's and Colitis.2023; 17(7): 1079. CrossRef
Factors contributing to flares of ulcerative colitis in North India- a case-control study
Vishavdeep Singh Rana, Gaurav Mahajan, Amol N. Patil, Anupam K. Singh, Vaneet Jearth, Aravind Sekar, Harjeet Singh, Atul Saroch, Usha Dutta, Vishal Sharma
BMC Gastroenterology.2023;[Epub] CrossRef
An education‐based telehealth group improves the management and clinical outcomes of patients with inflammatory bowel disease in China (THEIM study)
Jian Kang, Juan Su, Jing Wang, Haixia Ren, Anning Yin, Jiao Li, Qian Zhou, Yang Wang, Peng Zhu, Liping Zou, Wei Wang, Zhishun Tang, Weiguo Dong, Yijuan Ding, Ping An
United European Gastroenterology Journal.2023; 11(10): 960. CrossRef
Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening
Zohar Ben-Shatach, Tomer Ziv-Baran, Ella Fudim, Miri Yavzori, Orit Picard, Asaf Levartovsky, Limor Selinger, Batia Weiss, Uri Kopylov, Rami Eliakim, Bella Ungar
Therapeutic Advances in Gastroenterology.2022;[Epub] CrossRef
Medication Adherence and Its Influencing Factors Among Inflammatory Bowel Disease Patients in China
Fen Xu, Juping Tang, Zhiping Zhu, Yan Chen, Wen Hu, Sha Lu, Yunxian Zhou, Ding Lin
International Journal of General Medicine.2022; Volume 15: 4141. CrossRef
Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents
Dominic Pilon, Zhijie Ding, Erik Muser, Ameur M Manceur, Maude Vermette-Laforme, Marie-Hélène Lafeuille, Patrick Lefebvre
Crohn's & Colitis 360.2022;[Epub] CrossRef
Medication adherence in women with IBD of childbearing age likely associated with disease knowledge
Robyn Laube, Christian Selinger, Rupert W. Leong
Therapeutic Advances in Gastroenterology.2022;[Epub] CrossRef
Utility of the MARS-5 in Assessing Medication Adherence in IBD
James K Stone, Leigh Anne Shafer, Lesley A Graff, Lisa Lix, Kelcie Witges, Laura E Targownik, Clove Haviva, Kathryn Sexton, Charles N Bernstein
Inflammatory Bowel Diseases.2021; 27(3): 317. CrossRef
Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes
Chikako Watanabe, Masakazu Nagahori, Toshimitsu Fujii, Kaoru Yokoyama, Naoki Yoshimura, Taku Kobayashi, Hirokazu Yamagami, Kazuya Kitamura, Kagaya Takashi, Shiro Nakamura, Makoto Naganuma, Shunji Ishihara, Motohiro Esaki, Maria Yonezawa, Reiko Kunisaki, A
Digestive Diseases and Sciences.2021; 66(2): 577. CrossRef
Selected psychological predictors of medication adherence in the older adults with chronic diseases
Magdalena Gruszczyńska, Julia Wyszomirska, Anna Daniel‐Sielańczyk, Monika Bąk‐Sosnowska
Nursing Open.2021; 8(1): 317. CrossRef
Impacto de la pandemia covid-19 en la adherencia al tratamiento en pacientes con enfermedad inflamatoria intestinal: experiencia de un centro terciario en Chile
Rodrigo Quera, Daniela Simian, Lilian Flores, Patricio Ibáñez, Carolina Figueroa
Gastroenterología y Hepatología.2021; 44(9): 654. CrossRef
Adherence to Subcutaneous Biological Therapies in Patients with Inflammatory Rheumatic Diseases and Inflammatory Bowel Disease: A Systematic Review
Juan C Nieto, Claudia Arajol, Loreto Carmona, Carlos Marras, Luis Cea-Calvo
Immunotherapy.2021; 13(5): 433. CrossRef
Researching Interventions to Improve Medication Adherence in Ulcerative Colitis Patients
Mila Palma Pacheco, Flora Maria Lorenzo Fortes, Raquel Rocha dos Santos, Genoile Oliveira Santana Silva
Journal of Coloproctology.2021; 41(01): 096. CrossRef
Persistence as a Robust Indicator of Medication Adherence-Related Quality and Performance
Enrica Menditto, Caitriona Cahir, Sara Malo, Isabel Aguilar-Palacio, Marta Almada, Elisio Costa, Anna Giardini, María Gil Peinado, Mireia Massot Mesquida, Sara Mucherino, Valentina Orlando, Carlos Luis Parra-Calderón, Enrique Pepiol Salom, Przemyslaw Kard
International Journal of Environmental Research and Public Health.2021; 18(9): 4872. CrossRef
Effect of point‐of‐care gastrointestinal ultrasound on decision‐making and management in inflammatory bowel disease
Antony B. Friedman, Anil Asthana, Simon R. Knowles, Aphra Robbins, Peter R. Gibson
Alimentary Pharmacology & Therapeutics.2021; 54(5): 652. CrossRef
Impact of the COVID-19 pandemic on treatment adherence in patients with inflammatory bowel disease: Experience of a tertiary hospital in Chile
Rodrigo Quera, Daniela Simian, Lilian Flores, Patricio Ibáñez, Carolina Figueroa
Gastroenterología y Hepatología (English Edition).2021; 44(9): 654. CrossRef
Adherence to treatment in patients with inflammatory bowel disease
K. A. Andreev, A. V. Gorbenko, Yu. P. Skirdenko, N. A. Nikolaev, M. A. Livzan, G. R. Bikbavova, M. M. Fedorin
Bulletin of Siberian Medicine.2021; 20(3): 120. CrossRef
Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study
Juan Lasa, Gustavo Correa, Claudia Fuxman, Laura Garbi, Maria Eugenia Linares, Pablo Lubrano, Astrid Rausch, Martin Toro, Martin Yantorno, Ignacio Zubiaurre, Laurent Peyrin-Biroulet, Pablo Olivera
Gastroenterology Research and Practice.2020; 2020: 1. CrossRef
Knowledge of disease and self‐management of adolescents with inflammatory bowel diseases
Alex Krauthammer, Tal Harel, Noam Zevit, Dror S. Shouval, Raanan Shamir, Batia Weiss
Acta Paediatrica.2020; 109(10): 2119. CrossRef
The burden of cost in inflammatory bowel disease: a medical economic perspective
Jonathan A. Beard, Benjamin H. Click
Current Opinion in Gastroenterology.2020; 36(4): 310. CrossRef
İnflamatuar Bağırsak Hastalıkları Olan Bireylerde İlaç Uyumu ve Yaşam Kalitesi
Nazli ÖZTÜRK, Yasemin YILDIRIM
Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi.2020; 2(3): 192. CrossRef
Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus
Marco Daperno, Alessandro Armuzzi, Silvio Danese, Walter Fries, Giuseppina Liguori, Ambrogio Orlando, Claudio Papi, Mariabeatrice Principi, Fernando Rizzello, Angelo Viscido, Paolo Gionchetti
Gastroenterology Research and Practice.2019; 2019: 1. CrossRef
The Development of a Screening Tool to Identify and Classify Nonadherence in Inflammatory Bowel Disease
Aria Zand, Audrey Nguyen, Zack Stokes, Welmoed van Deen, Courtney Reynolds, Magdalena Dimitrova, Ariela Khandadash, Miriam Dvorsky, Jenny Sauk, Eric Esrailian, Daniel Hommes
Crohn's & Colitis 360.2019;[Epub] CrossRef
Adherence to therapy of patients with inflammatory bowel diseases
A I Parfenov, A V Kagramanova, A F Babayan, O V Knyazev
Terapevticheskii arkhiv.2018; 90(12): 4. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Medication non-adherence in inflammatory bowel diseases is associated with disability

Intest Res. 2018;16(4):571-578. Published online October 10, 2018

DOI: https://doi.org/10.5217/ir.2018.00033

XML Download

Figure

Related articles

Medication non-adherence in inflammatory bowel diseases is associated with disability

Fig. 1. Correlation between Medication Adherence Rating Scale (MARS) and the Inflammatory Bowel Diseases Disability Index (IBD-DI) according to acceptance of medications. Medication acceptance is defined as a subject’s perception of high medication necessity and low concerns according to their Beliefs about Medicines Questionnaire.

Fig. 1.

Medication non-adherence in inflammatory bowel diseases is associated with disability

	Adherent subjects (n=131)	Non-adherent subjects (n=42)^a	P-value
Demographic
Age (yr)	39 (26.5 to 51.5)	42 (30.75 to 53.25)	0.690
Female sex	65 (49.6)	24 (57.1)	0.400
CD	79 (60.3)	19 (45.2)	0.090
Referral hospital clinic attendance	86 (65.6)	5 (59.5)	0.470
Married/relationship	70 (53.4)	24 (57.1)	0.680
Crohn's and Colitis Australia membership	16 (12.2)	8 (19.0)	0.260
Previous IBD related hospitalization	52 (39.7)	15 (35.7)	0.640
Previous IBD related surgery	26 (19.8)	9 (21.4)	0.820
Medication regimen
Mesalazine	73 (55.7)	29 (69.0)	0.130
Immunomodulator	76 (58.5)	19 (45.2)	0.150
Corticosteroid	31 (23.7)	9 (21.4)	0.760
Anti-tumor necrosis factor α agent	32 (24.4)	5 (11.9)	0.085
Key questionnaire outcome measures
High medication concerns	58 (44.3)	31 (73.8)	0.001
High medication necessity	121 (92.4)	33 (78.6)	0.013
Medication acceptance	66 (50.4)	8 (19.0)	<0.001
Disability (IBD-DI score <3.5)	94 (71.8)	38 (90.5)	0.013
IBD-DI (score)	–2 (–9 to 5)	–16 (–26 to –6)	<0.001

Domain	IBD-DI score		P-value
Domain	Adherent subject (n=131)	Non-adherent subjects (n=42)	P-value
Overall health	–1 (–1.5 to 1.5)	–2 (–3 to –3)	<0.001
Body function	–6 (–10 to –2)	–11 (–16.6 to –5.4)	<0.001
Body structure	2 (1 to 3)	0 (–1.3 to 1.3)	<0.001
Activity participation	–2 (–4.5 to 0.5)	–6 (–9.5 to –2.5)	<0.001
Environmental factors	6 (2.5 to 9.5)	3 (0 to 6)	<0.001
Total score	–2 (–9.0 to 5.0)	–16 (–26.0 to –6.0)	<0.001

	Median difference in IBD-DI score	P-value
Socio-demographic
Age	–0.032^a	0.670
Female sex	–7.0	0.002
Married/relationship	–1.0	0.700
Crohn's & Colitis Australia membership	–1.5	0.730
Tertiary IBD clinic management	–5.5	<0.001
Disease characteristics
Diagnosis greater than 5 years ago	–3.0	0.390
UC diagnosis	1.0	0.405
Previous IBD related hospitalization	–4.5	0.010
Previous surgery	–4.0	0.035
Treatment modalities
5-ASA	0.5	0.500
Immunomodulator	–1.0	0.450
Steroids	–5.5	0.007
Biologicals	2.0	0.770
Beliefs about medications
High concerns	–5.0	<0.001
Low necessity	4.0	0.800
Lack of acceptance	–7.5	<0.001
Medication related behavior
Non-adherence	–14.0	<0.001

Clinical outcome	OR (95% CI)	β Coefficient	P-value
Fatigue	2.60 (0.71–9.46)	0.96	0.150
Low mood	0.53 (0.18–1.55)	–0.63	0.250
Anxiety	2.83 (0.91–8.81)	1.04	0.073
Abdominal pain	0.46 (0.17–1.23)	–0.78	0.120
Difficulty managing defecation	3.71 (1.50–9.16)	1.31	0.005
Presence of liquid stools	0.58 (0.23–1.47)	–0.54	0.250
Weight loss	1.74 (0.67–4.51)	0.55	0.260
Rectal bleeding	2.69 (1.14–6.36)	0.99	0.024
Arthralgia/arthritis	2.56 (1.11–5.92)	0.94	0.028

Table 1. Demographics of Respondents and Outcome Measures According to Medication Adherence

Value are presented as median (interqutile range) or number (%).

Non-adherence defined by Medication Adherence Reporting Scale score ≤16, range 4–20.

IBD-DI, Inflammatory Bowel Diseases Disability Index.

Table 2. IBD-DI Scores According to the International Classification of Functioning Domains Comparing Adherent versus Non-Adherent Subjects

Values are presented as median (interquartile range).

IBD-DI, Inflammatory Bowel Diseases Disability Index.

Table 3. Factors Associated with Disability as Measured by IBD-DI

Rho.

IBD-DI, Inflammatory Bowel Diseases Disability Index; 5-ASA, 5-aminosalicylic acid.

Table 4. Logistic Regression Model of Disease Features Associated with Medication Non-Adherence